Tuesday, 1 July 2025
  
Login

Australia's most trusted
source of pharma news

Tuesday, 01 July 2025
News

AZ scores blockbuster approval

Posted 19 October 2021 AM

AstraZeneca's projected blockbuster breast cancer drug Enhertu has won a provisional green-light from the TGA, with the company now turning its attention to securing subsidised access for Aussie patients.

"This approval marks a significant advance in the treatment of late stage, HER2+ breast cancer, for which there is currently no standard of care in Australia," AstraZeneca said in a company statement.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (4)

Sales & Customer Relations (10)

Clinical & Medical, R&D (11)

Regulatory, Pharmacovigilance & QA (1)

Devices (1)

Other (9)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.